

# Increased Expression of TIGIT And KLRG1 Correlates With Impaired CD56Bright NK Cell Immunity In HPV16-Related Cervical Intraepithelial Neoplasia

**Nie You**

Zhengzhou University

**Liu Dandan**

Fourth Medical Centre of Chinese PLA

**Yang Wen**

Chinese PLA General Hospital

**Li Yazhuo**

Chinese PLA General Hospital

**Zhang Lihua**

Chinese PLA General Hospital

**Cheng Xia**

Chinese PLA General Hospital

**Chen Ruyu**

Chinese PLA General Hospital

**Yuan Bingbing**

Zhengzhou University

**Zhang Guangzheng**

Zhengzhou University

**Wang Hongwei** (✉ [whw6626@sina.com](mailto:whw6626@sina.com))

Chinese PLA General Hospital

---

## Research Article

**Keywords:** cervical intraepithelial neoplasia, human papillomavirus 16, natural killer cell, cytokines, TIGIT-PVR, KLRG1-Cadherin

**Posted Date:** December 17th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-1156555/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

# Abstract

**Background:** The onset and progression of cervical intraepithelial neoplasia (CIN) are closely associated with the persistent infection of high-risk HPV (especially type16), which is mainly caused by immune escape. Natural killer (NK) cells play an important role against virally infected cells and tumor cells through a fine balance of signals from multiple surface receptors. Overexpression of non-MHC-I specific inhibitory receptors TIGIT, KLRG1, Siglec-7, LAIR-1, and CD300a on NK cells correlates with cellular exhaustion and immune evasion, but these receptors have not been investigated in CIN. The aim of the present study was to examine the potential role of NK cell non-MHC-I specific inhibitory receptors expression in immune escape from HPV16-related CIN patients .

**Methods:** the subset distribution, IFN- $\gamma$  and TNF- $\alpha$  expression levels and immunophenotype of TIGIT, KLRG1, Siglec-7, LAIR-1, and CD300a of NK cells were investigated in peripheral blood mononuclear cell samples by flow cytometry from 82 women, including HPV16(+) subjects with CIN 0, CIN I, and CIN II-III, and HPV subjects with CIN 0 (control). immunohistochemistry was applied to detect the expression of ligands for NK receptors in the cervical tissues. HPV types were identified by PCR assays.

**Results:** The HPV16(+) subjects with high-grade lesions had an increased number of circulating peripheral blood CD56<sup>bright</sup> NK cells with reduced functionality and IFN- $\gamma$  secretion. The expression levels of the inhibitory molecules TIGIT and KLRG1 on CD56<sup>bright</sup> NK cells increased in parallel with increasing CIN grade. In addition, TIGIT and KLRG1 related ligands, PVR, N-Cadherin and E-Cadherin expression level was also elevated with increasing CIN grade.

**Conclusions:** Our results suggested that the reduced viability of CD56<sup>bright</sup> NK cells and increased TIGIT and KLRG1 expression represent an escape mechanism associated to persistent HPV16 infection and CIN progression. These results may facilitate the development of early-warning immune predictors and therapeutic strategies for HPV16-associated CIN based on the TIGIT and KLRG1 inhibitory pathways of NK cells.

## 1. Introduction

Despite the existence of several effective preventive vaccines[1], cervical cancer remains the most common malignancies of the female genital tract. Persistent infection with high-risk subtype Human Papillomaviruses (HPV) [2, 3], especially HPV16, is a precursor of precancerous lesions of the cervix, also known as cervical intraepithelial neoplasia (CIN), which eventually leads to cancer in many cases[4, 5]. Natural killer cells are an important component of innate immunity and represent the first line of defense against viral infections. Activating and inhibitory receptors are expressed on the surface of NK cells and contribute to the NK cell activation[6]. Research has shown that NK cells appear in early HPV-infected lesions, can be essential to the pathogenesis of the lesions [7]. Most HPV infections are transient and self-limiting, nevertheless, in approximately 1-2% of the affected it might persist, suggesting that HPV may have evolved an escape strategy in response to the pursuit of NK cells by regulating its activation [8, 9]. Currently, the drivers for HPV to escape NK cell immune response in the occurrence and progression of CIN and cervical cancer are still unclear, especially the action mechanism of different NK cell subsets in the progression of HPV-related CIN.

In recent years, with the development of immune checkpoint blockade treatment, NK cells have shown promise for targeted therapy[10]. Previous studies have demonstrated that NK cells play a pivotal role in the immune response against early-stage HPV-associated CIN, especially in low-grade CIN tissues with a relatively low viral load. Besides, NK cells, especially the CD56<sup>bright</sup>NK cells with immunomodulatory properties, can infiltrate and attack cancerous tissues more easily. Unlike B cells and T cells, the activation of NK cells relies heavily on the recognition of major histocompatibility complex (MHC)-I-like molecules by inhibitory receptors to distinguish between “self” and “non-self” [6]. In fact, many virus-infected cells and cancer cells down-regulate the expression of MHC-I molecules to escape the detection of cytotoxic CD8<sup>+</sup>T cells. Remarkably, NK cells can recognize and respond to those target cells with “missing-self” phenotype and attack them[6, 11–13]. However, despite the loss of expression of MHC-I molecules, NK cells still show reduced function in patients with CIN and cervical cancer[14]. Based on this, we believe that this may be associated with the non-MHC-1 molecular pathway described by previous researchers[15]. TIGIT, KLRG1, Siglec-7, LAIR-1, and CD300a are important non-MHC-I inhibitory receptors on NK cells, involved in the NK cell-mediated regulation of various diseases[16–20]. However, it remains unclear whether non-MHC-I inhibitory receptors are expressed in HPV-16-associated CIN, or whether the activation of related pathways suppresses NK cell function and is associated with impaired viral clearance.

To assess the role of NK cells and these inhibitory receptors in the pathogenesis of CIN, we compared the subset distribution, interferon- $\gamma$  (IFN- $\gamma$ ) and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) expression levels and immunophenotype of peripheral blood NK cells between HPV16(+) subjects with different CIN grades and HPV16 subjects (control group). Further, we determined the expression of ligands corresponding to these inhibitory receptors in tissues of the cervix. We found that the upregulation of expression of TIGIT, KLRG1 on CD56<sup>bright</sup>NK cells and its ligands poliovirus receptor (PVR), E-Cadherin, N-Cadherin is directly associated with HPV16-related CIN, suggesting that NK cell surface inhibitory receptors may be the key components responsible for the compromised viral clearance due to impaired immunity in HPV16(+) subjects with CIN.

## 2. Materials And Methods

### 2.1 Study participants and procedures

All the participants were recruited from the Fourth Medical Center of the Chinese PLA(People’s Liberation Army) General Hospital, Beijing, China. HPV samples and biopsy specimens were obtained during the second colposcopy for female subjects whose liquid-based cytology results during the first visit returned positive for atypical squamous cells, low-grade squamous intraepithelial lesion, or high-grade squamous intraepithelial lesion. These specimens were subjected to independent histological analysis by three pathologists and categorized as no intraepithelial neoplasia (CIN 0), low-grade intraepithelial neoplasia (CIN I), and high-grade intraepithelial neoplasia (CIN II-III). The exclusion criteria were as follows: pregnancy, other infectious diseases, acute reproductive tract infections, receiving anti-inflammatory therapy, tumors, immunodeficiency, and receiving immunosuppressive agents. The final cohort of 82 participants was divided into four groups: (i) 26 HPV16 subjects with CIN 0; (ii) 17 HPV16(+) subjects with CIN 0; (iii) 16 HPV16(+) subjects with CIN I; (iv) 23 HPV16(+) subjects with CIN II-III. In addition, archival paraffin-embedded tissue samples were also collected and categorized into the above-mentioned four groups, each of which comprised 100 cases. All participants recruited in this study were aged between 20 and 60 ( $37.68 \pm 10.36$  years) and had signed an informed consent

form. This study was reviewed and approved by the hospital ethics committee: Ethics Committee of the Fourth Medical Center of PLA General Hospital(2021KY006-HS001).

## **2.2 Polymerase chain reaction (PCR) for HPV DNA typing**

Cervical cytobrushes used to collect cervical exfoliated cells were placed into 10 ml gigenespecimen transport medium (Qiagen) and DNA was extracted from the cervical samples using the DNeasy tissue kit (Qiagen), according to the manufacturer's instructions. The DNA was then subjected to qualitative PCR using specific primers. The  $\beta$ -Globin was amplified to verify that the samples contained DNA of sufficient quality and quantity for the HPV test. Water was used as a negative control in each PCR experiment.

## **2.3 Flow cytometry**

Blood samples (100  $\mu$ l) collected from the participants were incubated for 25 min at 25°C in a flow cytometry tube with the following specific antibodies (5  $\mu$ l each): CD3 (563219, BD), CD16 (302018, Biolegend), CD56 (555518, BD), TIGIT (12-9500-42, eBioscience), DNAM-1 (559788, BD), NKG2A (130-113-565, Miltenyi Biotec), LAIR-1 (ab27744, Abcam), Siglec-7 (ab200558, Abcam), and KLRG1 (25-9488-42, eBioscience). In addition, an isotype control was prepared for each sample. After incubation, the reaction mixture in each tube was mixed thoroughly with 2 ml of hemolysin. The samples were then washed for flow cytometry analysis (BD FACSCanto™ Flow Cytometer) within 4 h. .

## **2.4 Cytokine flow cytometry assay**

3  $\mu$ l of blood samples were collected from the participants and subjected to density gradient centrifugation to isolate peripheral blood mononuclear cells (PBMC). After being washed and resuspended, freshly isolated PBMCs were seeded at a density of  $10^6$  cells/well and incubated with 100 ng/ml of phorbol myristate acetate(524400, sigma), 1  $\mu$ g/ml of ionomycin(407951, sigma), and 10  $\mu$ g/ml of brefeldin A(555029, BD) at 37°C and 5% CO<sub>2</sub> for 6 h. Subsequently, the stimulated cells were incubated with 5  $\mu$ l of CD56, CD3, CD16, and isotype controls (as mentioned above) in the dark at 25 °C for 25 min for cell surface labeling. The cells were then fixed and permeabilized using Fixation/Permeabilization Solution kit (555028, BD) and incubated in the dark with 10  $\mu$ l of anti-IFN- $\gamma$  (552887, BD) and 8  $\mu$ l of anti-TNF- $\alpha$  (562083, BD) at 4°C for 30 min. After washing, the samples were loaded for flow cytometry assay.

## **2.5 Immunohistochemical (IHC) assay**

Cervical biopsy samples were routinely embedded in paraffin and sectioned at a thickness of 3  $\mu$ m, followed by hematoxylin-eosin (HE) staining. The HE-stained tissue sections were then examined by three experienced pathologists. Prior to IHC staining, the tissue sections were dewaxed in xylene and rehydrated in graded alcohol. The tissue sections were incubated with the following antibodies: PVR (ab267389, diluted at a ratio of 1:300, Abcam), E-Cadherin and N-Cadherin (MAB0738 and MAB0571, respectively, diluted at a ratio of 1:200, MXB Biotechnologies), followed by IHC staining using the streptavidin-peroxidase conjugate method. Negative controls were prepared with non-immune isotype-specific sera used in place of primary antibodies, while previously positively-stained tissue sections for the labeled proteins were taken as positive controls.

## **2.6 Statistical analysis**

Statistical analysis was performed using GraphPad 8.0.1. Flow cytometry data were expressed as percentages and median fluorescence intensity (MFI). A nonparametric test (Kruskal–Wallis test) was used to determine statistical significance. In experiments involving histology or IHC, the figures shown are representative of the tissue sections. The Allred scoring system was used for IHC staining quantification[21]. Proportion scores were: 0, none; 1, less than one percent; 2, one percent to one tenth; 3, one tenth to one third; 4, one third to two thirds; 5, Two thirds or more. The intensity scores were: 1 for weak, 2 for medium, and 3 for strong. We evaluated 10 high-power fields ( $\times 400$  magnification) in each sample. Added the average of the intensity score and the proportional score as the Allred total score (range = 0-8). The image was captured with an Olympus BX40F microscope (Olympus). All statistical assessments were two-sided, and statistical significance was defined as  $P < 0.05$ .

## 3. Results

### 3.1 Increased peripheral blood CD56<sup>bright</sup> NK cells counts in HPV16(+)-related CIN II-III

The circulating NK cell (CD3<sup>-</sup>CD56<sup>+</sup>) subpopulations in the blood samples of the subjects from each group were analyzed by flow cytometry with appropriate gating strategies (Fig. 1A). Table 1 and Fig. 1B a-c show the distribution of total NK cells, CD56<sup>bright</sup> NK cells, and CD56<sup>dim</sup> NK cells in each group. The CIN II-III group showed an increasing trend in the proportion (percentage relative to total NK cells) of circulating CD56<sup>bright</sup> NK cells ( $P = 0.099$ ) and a slightly lower proportion of circulating CD56<sup>dim</sup> NK cells than the HPV CIN 0 group and the HPV16(+) low-grade lesion group, although these differences were not statistically significant. Subsequently, the number of cells per microliter of circulating blood for each NK cell subpopulation in each group was calculated based on lymphocyte counts obtained via blood routine test.. The CIN II-III group showed a significantly higher absolute count of CD56<sup>bright</sup> NK cells than the HPV16(+) CIN 0 group ( $P = 0.036$ ) (Table 1, Fig. 1e), while there were no statistically significant differences in the absolute count of CD56<sup>dim</sup> NK cells between the groups. Further, there were no significant differences in the percentage and absolute count of the total circulating NK cells between the groups.

### 3.2 Decreased peripheral blood CD56<sup>bright</sup> NK cells function in HPV16(+)-related CIN II-III

The expression of immunomodulatory cytokines, such as interferon- $\gamma$  (IFN- $\gamma$ ) and TNF- $\alpha$ , is believed to affect persistent HPV infection and CIN progression. We further examined the ability of peripheral blood NK cell subpopulations to secrete IFN- $\gamma$  and TNF- $\alpha$  via flow cytometry. The results showed that the CD56<sup>bright</sup> NK cell subpopulation had a significantly higher secretion level of IFN- $\gamma$  than the CD56<sup>dim</sup> NK cell subpopulation in the HPV CIN 0 (control) group ( $P = 0.015$ ), while the CD56<sup>dim</sup> NK cell subpopulation had a significantly higher secretion level of TNF- $\alpha$  than the CD56<sup>bright</sup> NK cell subpopulation ( $P = 0.026$ ) (Fig. 2Ba, b). However, the secretion level of IFN- $\gamma$  by CD56<sup>bright</sup> NK cells decreased with increasing CIN grade (Fig. 2Bc). Despite an increase in absolute count, the CD56<sup>bright</sup> NK cells in the HPV16(+) CIN II-III group displayed significantly lower secretion of IFN- $\gamma$  than that of the HPV CIN 0 group ( $P = 0.004$ ) (Fig. 2Bc). There were no significant differences in the secretion level of TNF- $\alpha$  by CD56<sup>dim</sup> NK cells between groups.

### 3.3 Increased TIGIT and KLRG1 expression on CD56<sup>bright</sup> NK cells in HPV16(+)-related CIN

We further examined the expression of the inhibitory receptors TIGIT, NKG2A, CD300a, KLRG1, LAIR1, and Siglec-7 on circulating peripheral blood NK cells- in samples of different groups. The results showed that the HPV16(+) CIN II-III group had a significantly higher percentage of TIGIT-positive CD56<sup>bright</sup> NK cells than the HPV CIN 0 group (P = 0.019) (Fig. 3a). However, there was no significant difference in the MFI of TIGIT on CD56<sup>bright</sup> NK cells between the HPV CIN 0 group and the HPV16(+) CIN groups (P = 0.114) (Table 1). Both the HPV16(+) CIN 0 group (P = 0.017) and the CIN I group (P < 0.0001) displayed a significantly higher percentage of KLRG1-positive CD56<sup>bright</sup> NK cells than the HPV CIN 0 group (Fig. 3g). However, the CIN II-III group had a lower percentage of KLRG1-positive CD56<sup>bright</sup> NK cells than the CIN I group (P = 0.002) (Fig. 3g). Similarly, we observed a comparable differential distribution of the MFI of KLRG1 on CD56<sup>bright</sup> NK cells between different groups (P = 0.021) (Table 1). In addition, we observed that the CIN II-III group had a significantly higher expression level of KLRG1 on CD56<sup>dim</sup> NK cells than the HPV CIN 0 group (P = 0.026) (Fig. 3h). There were no differences in other NK cell inhibitory phenotypic markers between the HPV16(+) CIN groups and the HPV CIN 0 group (Fig. 3b-f, i-l) (Table 1).

### 3.4 Increased expression of PVR, N-Cadherin and E-Cadherin in HPV16(+)-related CIN

In order to explore the potential mechanism by which HPV16 persistent infection mediates the characteristic phenotype and function suppression of NK cells, we next detected the expression level of PVR (the ligand of TIGIT) and E-Cadherin and N-Cadherin (the ligands of KLRG1) in cervical tissues by immunohistochemical staining. As a member of the Nectin-like protein family, PVR exhibited minor expression in the epithelial layer and stroma of normal cervical tissues. However, comparing with control, an increased expression of PVR in the HPV16(+) groups, particularly in the CIN II-III and CIN I group, was significant (P < 0.0001), and the PVR expression level rised with increasing CIN grade (Fig. 4Aa, 4Ba). E-Cadherin and N-Cadherin are known to be important for maintaining membrane integrity and cell function. They were normally expressed on the cell membrane of the epithelial layer, and no difference was observed in the expression intensity between the normal HPV16(+) CIN0 and the control group. However, the expression levels of HPV16(+) CIN I group and CIN II-III group were significantly higher than that of the control group (P < 0.0001), and the expression of E-Cadherin and N-Cadherin increased with the increasing CIN grade (Fig. 4 A b, c; 4Bb, c)

## 4. Discussion

Persistent high-risk HPV infection is the most important risk factor of cervical cancer, and the virus clearance barrier caused by immune escape is a key link in the persistent infection of HPV[22]. Prompt detection and clearance of HPV by the acquired immune system are rarely attained, as HPV is an epitheliotropic virus that often establishes local infections. NK cells are incapable of preventing persistent HR-HPV infections among specific populations despite exhibiting effective antiviral activity during the early stage of viral infection. Thus, an in-depth investigation of the evasion mechanism from NK cell-mediated immune responses by HPV is of great clinical significance for the development of therapeutic vaccines and drugs, the elimination of persistent HPV infection, and the effective prevention of cervical cancer[23].

In this study, we investigated the expression of inhibitory receptors and secretion levels of IFN- $\gamma$  and TNF- $\alpha$  in CD56<sup>bright</sup> and CD56<sup>dim</sup> NK cells among the HPV(+) CIN groups and the HPV CIN 0 group. The results revealed that the HPV(+) CIN groups had a significantly increased number of CD56<sup>bright</sup> NK cells and significantly

reduced ability to secrete IFN- $\gamma$ . Further, the expression of the inhibitory receptors TIGIT and KLRG1, as well as their ligands PVR, N-Cadherin and E-Cadherin were significantly increased, suggesting that the activation of the TIGIT and KLRG1 axes may facilitate the immune evasion of HPV16 by suppressing the functionality of CD56<sup>bright</sup> NK cells, thereby leading to persistent infection and promoting the onset and progression of CIN.

NK cells play a key role in the early control of viral infections and tumor immunosurveillance[24, 25]. CD56<sup>dim</sup>CD16<sup>+</sup> NK cells, which account for approximately 90% of circulating NK cells, carry high levels of perforin and granzyme in the cytoplasm and primarily exert cytotoxic effects[26]. CD56<sup>bright</sup> NK cells, which account for about 10% of circulating NK cells and are widely present in the human liver and uterus, secrete high levels of cytokines and are key components of the first line of host defense against viral infections. Previous studies have shown that CD56<sup>bright</sup> NK cells perform important functions in the clearance of HPV-, hepatitis B virus-, and respiratory syncytial virus-infected cells in the early stages, as well as in the prevention of persistent viral infections[27–30]. In some diseases, the CD56<sup>bright</sup> NK cell subset may be selectively expanded due to its unique cytokine profile, which is consistent with our findings[31]. Our study showed that subjects in the HPV16(+) CIN II-III group had a significantly increased number of circulating CD56<sup>bright</sup> NK cells. Similarly, the number of circulating NK cells increased, with significantly elevated secretion levels of IFN- $\gamma$  and TNF- $\alpha$  in the early stage of acute HBV infection. However, different ligands and cytokines render NK cells tolerant to HBV and reduce their antiviral capacity following the progression to chronic infection[32, 33].

In this regard, we speculated that the infection of HPV may locally inhibit the immunomodulatory activity of CD56<sup>bright</sup> NK cells via certain mechanisms, leading to the compensatory proliferation of this particular NK cell subpopulation. Our subsequent analysis of the ability of the circulating NK cells to secrete effector cytokines showed that CD56<sup>bright</sup> and CD56<sup>dim</sup> NK cells in healthy subjects exhibited a remarkable ability to secrete IFN- $\gamma$  and TNF- $\alpha$ , respectively. However, NK cells, particularly CD56<sup>bright</sup> NK cells, in subjects with CIN exhibited a significantly reduced ability to secrete IFN- $\gamma$ , which is consistent with previous findings[34, 35]. Taken together, these findings indicate that the effector function of CD56<sup>bright</sup> NK cells is reduced during the progression of HPV16-related CIN, and that the increased number of CD56<sup>bright</sup> NK cells did not contribute to the timely clearance of virus-infected cells.

NK cell activation are balanced by signals transduced by activating or inhibitory receptors[36]. Under normal conditions, activation relies heavily on the inhibitory receptor to recognize MHC-I molecules to distinguish "self" from "non-self". Decreased expression or structural abnormalities in MHC-I molecules on the surface of virus-infected cells and tumor cells affect the recognition of ligands by corresponding inhibitory receptors on NK cells, thereby activating NK cells. However, There are also multiple non MHC-I specific inhibitory receptors on NK cells. Some studies have reported that during infections with down-regulated expression of MHC-I molecules, these inhibitory receptors participate in virus immune escape[37]. HPV-mediated immune evasion of CIN and cervical cancer is often accompanied by downregulation of the MHC-I molecules, in which case NK cells are activated to mediate HPV clearance[14]. However, findings from previous studies as well as the current study have revealed varying degrees of reduction in NK cells, suggesting the involvement of alternative mechanisms to prevent NK cell activation. In one such mechanism, NK cells express several non-MHC-I specific receptors that play a crucial role in recognizing viral infections and tumor cells, thereby contributing toward viral immune evasion[14]. Our results confirmed the immunophenotypic alteration of circulating CD56<sup>bright</sup> NK cells

characterized by the increased expression of the non-MHC-I receptors TIGIT and KLRG1 in subjects with HPV16(+) CIN.

Previous studies have indicated that the inhibitory interaction of the TIGIT-PVR axis is critical for the functional heterogeneity of NK cells, by which it negatively regulates cell viability and induces immune tolerance[32, 33]. Johnston et al[38] had previously demonstrated that TIGIT was significantly upregulated in tumor-infiltrating lymphocytes in endometriosis, breast cancer, clear cell renal cell carcinoma, non-small cell lung cancer, and colorectal cancer. In addition, patients infected with human immunodeficiency virus (HIV) had a higher TIGIT expression level in NK cells than HIV. In this study, researchers found that high levels of TIGIT reversibly inhibited IFN- $\gamma$  production in the NK cells[39]. We observed that PVR, the ligand of TIGIT, had a relatively high expression level in HPV16(+) subjects with CIN, which not only suppressed the function of immune cells by excessively binding to TIGIT, but altered various cellular behaviors, accelerated cell proliferation and reduced intercellular adhesion thereby further promoting tumor progression. These results suggest that the TIGIT-PVR pathway may be an important negative regulator that induces the immune evasion of HPV16. In fact, clinical trials of anti-TIGIT antibodies are ongoing. For instance, the Phase II CITYSCAPE trial evaluated the combination of tiragolumab (anti-TIGIT antibody) and atezolizumab (anti-PD-L1 antibody) in the treatment of non-small cell lung cancer with encouraging results [40].

KLRG1 is another important non-MHC-I specific receptor on NK cells. Cadherin type I, such as E, N cadherin, has been identified as the ligand of KLRG1[41]. KLRG1 is a transmembrane receptor of the lectin-like superfamily predominantly mediating inhibitory effect through the cytoplasmic ITIM motif. Previous studies showed that KLRG1 was rapidly upregulated on NK cells, CD8<sup>+</sup> and CD4<sup>+</sup> T cells during chronic infections with the human cytomegalovirus, Epstein-Barr virus, and HIV[41, 42]. Additionally, it was found that the expression of KLRG1 increased in chronic hepatitis C[43]. Ito et al.[42] showed that the interaction of cadherin with KLRG1 activated the inhibitory pathway of NK cells. Nevertheless, other report found that the function of KLRG1 axis mainly inhibited CD8<sup>+</sup> T cells, but had little effect on NK cells. Our results showed the expression of KLRG1 on circulating CD56<sup>bright</sup> NK cells was increased primarily in HPV16(+) subjects with CIN 0 and CIN I. Although its characteristic expression in peripheral blood circulation was not found in high-grade CIN, cervical histochemical results showed that the expression of its ligands E, N-cadherin in CIN II-III was significantly increased, and E - Cadherin was also increased in CIN I. It may be noted that even though the expression of E-cadherin is reduced in most tumor studies to increase cell invasiveness, correlation studies showed that some tumors may paradoxically use KLRG1-cadherin to evade immune surveillance. For example, in invasive breast cancer, E-cadherin was down-regulated initially by some tumor cells to acquire metastatic potential, and then it was re-expressed to promote adhesion and evade immune attack[44]. It is still noteworthy that the KLRG1 expression on circulating CD56<sup>dim</sup> NK cells was increased significantly, which needs to be investigated in future experiments to clarify the effect of CD56<sup>dim</sup> NK cells on HPV16-related CIN. Our results suggests that the potential role of KLRG1 in mediating innate immune evasion of HPV16.

## 5. Conclusion

Our results suggested that the reduced viability of CD56<sup>bright</sup> NK cells and increased TIGIT and KLRG1 expression represent an escape mechanism associated to persistent HPV16 infection and CIN progression. This indicated that the increased number of TIGIT<sup>+</sup>, KLRG1<sup>+</sup>CD56<sup>bright</sup> NK cells may serve as an early marker of

HPV16-related CIN progression. It is highly anticipated that anti-TIGIT and/or KLRG1 immunotherapy may bring hope to patients with HPV16-related CIN

## Abbreviations

CIN, cervical intraepithelial neoplasia; HE, hematoxylin-eosin, HR-HPV, high-risk human papillomavirus; IHC, immunohistochemistry; IFN- $\gamma$ , interferon- $\gamma$ ; KLRG1, killer cell lectin-like receptor G1; LAIR-1, leukocyte-associated Ig-like receptor-1; MHC, major histocompatibility complex; MFI, median fluorescence intensity; NK, natural killer cells; PBMC, peripheral blood mononuclear cell; PVR, poliovirus receptor; Siglec, sialic acid-binding immunoglobulin-like lectins; TIGIT, T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain; TNF- $\alpha$ , tumor necrosis factor- $\alpha$

## Declarations

### Ethics approval and consent to participate

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### Consent for publication

We warrant that all authors have seen and approved the manuscript, contributed significantly to the work, and the manuscript has not been previously published nor is not being considered for publication elsewhere.

### Availability of data and materials

Not applicable

### Competing interests

No potential conflict of interest was reported by the authors.

### Funding

This work was supported by the National Natural Science Foundation of China under Grant 81000848 and 81571519.

### Authors' contributions

N.Y., L.D.D and Y.W. contributed to the conception of the study; N.Y, L.D.D, L.Y.Z, Z.L.H, C.X, C.R.Y, Y.B.B performed the experiments; N.Y., L.D.D., Y.W. Z.G.Z, W.H.W contributed significantly to analysis and manuscript preparation; Z.G.Z, W.H.W helped perform the analysis with constructive discussions. All authors read and approved the final manuscript.

### Acknowledgements

Not applicable

## References

1. Cohen PA, Jhingran A, Oaknin A, Denny L: Cervical cancer. *Lancet* (London, England) 2019, 393(10167).
2. Liu Y, Guo JZ, Liu Y, Wang K, Ding W, Wang H, Liu X, Zhou S, Lu XC, Yang HB et al: Nuclear lactate dehydrogenase A senses ROS to produce  $\alpha$ -hydroxybutyrate for HPV-induced cervical tumor growth. *Nature communications* 2018, 9(1).
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *The Journal of pathology* 1999, 189(1).
4. Zhu B, Xiao Y, Yeager M, Clifford G, Wentzensen N, Cullen M, Boland JF, Bass S, Steinberg MK, Raine-Bennett T et al: Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance. *Nature communications* 2020, 11(1).
5. Sample KM: DNA repair gene expression is associated with differential prognosis between HPV16 and HPV18 positive cervical cancer patients following radiation therapy. *Scientific reports* 2020, 10(1).
6. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S: Functions of natural killer cells. *Nature immunology* 2008, 9(5).
7. Frazer IH: Interaction of human papillomaviruses with the host immune system: a well evolved relationship. *Virology* 2009, 384(2).
8. Li W, Tian S, Wang P, Zang Y, Chen X, Yao Y, Li W: The characteristics of HPV integration in cervical intraepithelial cells. *J Cancer* 2019, 10(12).
9. Gensterblum-Miller E, Brenner JC: Protecting Tumors by Preventing Human Papilloma Virus Antigen Presentation: Insights from Emerging Bioinformatics Algorithms. *Cancers (Basel)* 2019, 11(10).
10. Hodgins JJ, Khan ST, Park MM, Auer RC, Ardolino M: Killers 2.0: NK cell therapies at the forefront of cancer control. *The Journal of clinical investigation* 2019, 129(9).
11. Lodoen MB, Lanier LL: Viral modulation of NK cell immunity. *Nature reviews Microbiology* 2005, 3(1).
12. Parham P: MHC class I molecules and KIRs in human history, health and survival. *Nature reviews Immunology* 2005, 5(3).
13. Kärre K, Ljunggren HG, Piontek G, Kiessling R: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. *Nature* 1986, 319(6055).
14. Garzetti GG, Ciavattini A, Muzzioli M, Goteri G, Mannello B, Romanini C, Fabris N: Natural killer cell activity in patients with invasive cervical carcinoma: importance of a longitudinal evaluation in follow-up. *Gynecologic and obstetric investigation* 1995, 40(2).
15. Kumar V, McNerney ME: A new self: MHC-class-I-independent natural-killer-cell self-tolerance. *Nature reviews Immunology* 2005, 5(5).
16. Harjunpää H, Guillerey C: TIGIT as an emerging immune checkpoint. *Clinical and experimental immunology* 2020, 200(2).
17. Henson SM, Akbar AN: KLRG1—more than a marker for T cell senescence. *Age (Dordrecht, Netherlands)* 2009, 31(4).
18. Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, Démoulin T, Schneider C, Wehrli M, Hunger RE, Baerlocher GM et al: Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent

- tumor immunosurveillance. *The Journal of clinical investigation* 2014, 124(4).
19. Vitallé J, Terrén I, Orrantia A, Zenarruzabeitia O, Borrego F: CD300 receptor family in viral infections. *European journal of immunology* 2019, 49(3).
  20. Sivori S, Della Chiesa M, Carlomagno S, Quatrini L, Munari E, Vacca P, Tumino N, Mariotti FR, Mingari MC, Pende D et al: Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer. *Frontiers in immunology* 2020, 11
  21. Elledge RM, Clark GM, Fuqua SA, Yu YY, Allred DC: p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. *Cancer Res* 1994, 54(14).
  22. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Hernandez-Avila M et al: Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. *Cancer Epidemiol Biomarkers Prev* 2011, 20(2).
  23. Myers JA, Miller JS: Exploring the NK cell platform for cancer immunotherapy. (1759-4782 (Electronic)).
  24. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S: Innate or adaptive immunity? The example of natural killer cells. *Science* 2011, 331(6013).
  25. Della Chiesa M, Marcenaro E, Sivori S, Carlomagno S, Pesce S, Moretta A: Human NK cell response to pathogens. *Semin Immunol* 2014, 26(2).
  26. Bozzano F, Marras F, De Maria A: Natural Killer Cell Development and Maturation Revisited: Possible Implications of a Novel Distinct Lin(-)CD34(+)DNAM-1(bright)CXCR4(+) Cell Progenitor. *Front Immunol* 2017, 8
  27. Textor S, Dürst M, Jansen L, Accardi R, Tommasino M, Trunk MJ, Porgador A, Watzl C, Gissmann L, Cerwenka A: Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. *International journal of cancer* 2008, 123(10).
  28. Heeg M, Thimme R: Natural killer cells and hepatitis C: natural killer p46 expression linked to antiviral and antifibrotic activity. *Hepatology* 2012, 56(4).
  29. Jiang Y, Cui X, Cui C, Zhang J, Zhou F, Zhang Z, Fu Y, Xu J, Chu Z, Liu J et al: The function of CD3+CD56+ NKT-like cells in HIV-infected individuals. *BioMed research international* 2014, 2014
  30. Tarazona R, Lopez-Sejas N, Guerrero B, Hassouneh F, Valhondo I, Pera A, Sanchez-Correa B, Pastor N, Duran E, Alonso C et al: Current progress in NK cell biology and NK cell-based cancer immunotherapy. *Cancer Immunol Immunother* 2020, 69(5).
  31. Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J: CD56bright natural killer (NK) cells: an important NK cell subset. *Immunology* 2009, 126(4).
  32. Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H et al: The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. *Proc Natl Acad Sci U S A* 2009, 106(42).
  33. Stanietsky N, Rovis TL, Glasner A, Seidel E, Tsukerman P, Yamin R, Enk J, Jonjic S, Mandelboim O: Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. *Eur J Immunol* 2013, 43(8).
  34. Acebes-Huerta A, Lorenzo-Herrero S, Folgueras AR, Huergo-Zapico L, Lopez-Larrea C, Lopez-Soto A, Gonzalez S: Drug-induced hyperploidy stimulates an antitumor NK cell response mediated by NKG2D and DNAM-1 receptors. *Oncoimmunology* 2016, 5(2).

35. Zhang J, Jin S, Li X, Liu L, Xi L, Wang F, Zhang S: Human Papillomavirus Type 16 Disables the Increased Natural Killer Cells in Early Lesions of the Cervix. *J Immunol Res* 2019, 2019
36. Balaji GR, Aguilar OA, Tanaka M, Shingu-Vazquez MA, Fu Z, Gully BS, Lanier LL, Carlyle JR, Rossjohn J, Berry R: Recognition of host Clr-b by the inhibitory NKR-P1B receptor provides a basis for missing-self recognition. *Nat Commun* 2018, 9(1).
37. Zeleznjak J, Lisnic VJ, Popovic B, Lisnic B, Babic M, Halenius A, L'Hernault A, Rovis TL, Hengel H, Erhard F et al: The complex of MCMV proteins and MHC class I evades NK cell control and drives the evolution of virus-specific activating Ly49 receptors. *J Exp Med* 2019, 216(8).
38. Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B et al: The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. *Cancer Cell* 2014, 26(6).
39. Yin X, Liu T, Wang Z, Ma M, Lei J, Zhang Z, Fu S, Fu Y, Hu Q, Ding H et al: Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals. *Front Immunol* 2018, 9
40. Ho DW, Tsui YM, Chan LK, Sze KM, Zhang X, Cheu JW, Chiu YT, Lee JM, Chan AC, Cheung ET et al: Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. *Nat Commun* 2021, 12(1).
41. Colonna M: Cytolytic responses: cadherins put out the fire. *J Exp Med* 2006, 203(2).
42. Ito M, Maruyama T, Saito N, Koganei S, Yamamoto K, Matsumoto N: Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. *J Exp Med* 2006, 203(2).
43. Sene D, Levasseur F, Abel M, Lambert M, Camous X, Hernandez C, Pene V, Rosenberg AR, Jouvin-Marche E, Marche PN et al: Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines. *PLoS Pathog* 2010, 6(11).
44. Cowin P, Rowlands TM, Hatsell SJ: Cadherins and catenins in breast cancer. *Curr Opin Cell Biol* 2005, 17(5).

## Table

**Table 1: Comparison between peripheral blood NK cell subsets in patients from the HPV16(+) CIN groups and the HPV(-) CIN 0 group**

	CIN 0 HPV(-) (N=20)		CIN 0 HPV16(+) (N=11)		CIN I HPV16(+) (N=10)		CIN II-III HPV16(+) (N=16)		P value
	Median	IQR	Median	IQR	Median	IQR	Median	IQR	
<b>Subset distribution</b>									
CD3 <sup>+</sup> CD56 <sup>+</sup> NK cells(%)	16.69	11.85-20.47	14.66	6.84-19.81	10.04	7.38-19.37	14.33	8.04-22.02	0.555
CD3 <sup>+</sup> CD56 <sup>+</sup> NK cells(count)	256.6	177.0-380.4	194.6	136.7-305.8	307.4	155.5-344.1	232.2	179.3-373.3	0.407
CD56 <sup>bright</sup> NK cells (%)	3.090	1.258-5.195	3.420	1.918-5.423	3.030	1.830-6.990	5.730	2.518-6.965	0.303
CD56 <sup>bright</sup> NK cells (count)	8.301	3.409-12.23	5.864	4.499-6.948	7.630	5.318-10.27	12.84	6.793-23.21	<b>0.036</b>
CD56 <sup>dim</sup> NK cells (%)	94.95	90.31-98.02	96.38	92.70-97.94	94.60	90.78-97.79	91.33	83.90-95.45	0.099
CD56 <sup>dim</sup> NK cells (count)	248.0	166.6-365.8	183.9	129.1-302.4	296.1	149.5-333.0	214.1	146.6-354.2	0.623
<b>CD56<sup>dim</sup> NK cells</b>									
TIGIT <sup>+</sup> (%)	83.64	79.99-88.62	80.78	70.81-88.13	77.24	70.16-82.53	80.07	75.37-88.53	0.241
TIGIT <sup>+</sup> (MFI)	2388	1873-3252	2122	1306-3254	1685	1399-2301	2080	1746-3246	0.234
CD226 <sup>+</sup> (%)	85.50	82.95-91.89	90.20	84.59-93.78	84.65	71.54-91.45	90.19	77.74-93.78	0.628
CD226 <sup>+</sup> (MFI)	1447	1364-1591	1596	1171-1739	1381	825.5-1475	1617	1210-1760	0.349
NKG2A <sup>+</sup> (%)	29.46	15.88-47.20	38.91	33.96-48.97	34.64	27.29-43.55	29.83	23.68-42.14	0.684
NKG2A <sup>+</sup> (MFI)	174.0	161.1-459.2	234.9	206.9-518.9	204.9	179.8-281.7	197.0	166.2-1074	0.406
CD300a <sup>+</sup> (%)	98.74	94.87-99.29	98.32	97.36-98.98	98.33	97.04-98.75	97.87	96.67-98.86	0.804
CD300a <sup>+</sup> (MFI)	2927	2087-3686	2733	1428-3403	3476	2788-4333	2688	1955-3923	0.366
LAIR-1 <sup>+</sup> (%)	98.85	96.27-99.52	99.41	98.44-99.79	98.26	97.34-98.87	98.39	96.31-99.28	0.137
LAIR-1 <sup>+</sup> (MFI)	2086	1321-2665	2798	2283-3064	1615	1442-2464	2012	1436-2392	0.256

Siglec7 <sup>+</sup> (%)	83.47	72.28-93.31	79.49	74.96-89.36	76.54	59.39-87.95	79.61	65.22-92.51	0.624A
Siglec7 <sup>+</sup> (MFI)	11164	7120-16912	8153	4350-13496	6774	2256-10904	10199	4249-19750	0.280
KLRG-1 <sup>+</sup> (%)	24.40	20.63-38.53	25.73	16.89-41.76	45.69	31.26-53.97	40.38	33.43-52.90	<b>0.006</b>
KLRG-1 <sup>+</sup> (MFI)	214.0	143.9-487.8	310.6	222.5-603.3	328.1	161.8-738.5	498.5	262.3-1020	0.122
<b>CD56<sup>bright</sup> NK cells</b>									
TIGIT <sup>+</sup> (%)	23.02	15.12-33.16	28.72	24.55-34.03	26.34	17.79-32.73	35.24	29.63-38.51	<b>0.019</b>
TIGIT <sup>+</sup> (MFI)	150.9	125.9-199.0	164.0	132.6-194.3	156.0	119.2-228.6	199.8	173.3-221.3	0.114
CD226 <sup>+</sup> (%)	96.29	94.83-98.12	97.10	93.95-97.67	97.48	76.04-98.87	96.10	93.19-97.63	0.742
CD226 <sup>+</sup> (MFI)	1918	1729-2218	2155	1370-2243	1717	768.1-2618	2085	1756-2324	0.916
NKG2A <sup>+</sup> (%)	87.67	82.71-91.40	93.06	84.70-95.57	92.51	89.78-95.90	92.81	86.77-96.00	0.057
NKG2A <sup>+</sup> (MFI)	5289	4741-7657	6854	5260-9279	6817	5103-9407	6764	4965-7938	0.291
CD300a <sup>+</sup> (%)	99.57	98.49-100.0	99.56	98.62-99.94	99.21	98.69-99.69	100.0	99.03-100.0	0.362
CD300a <sup>+</sup> (MFI)	7325	5285-8500	5945	4488-9307	9753	6058-12490	8092	5945-10576	0.199
LAIR-1 <sup>+</sup> (%)	99.45	97.89-99.74	99.51	99.03-99.87	99.21	97.66-99.76	99.61	98.97-100.0	0.458
LAIR-1 <sup>+</sup> (MFI)	2811	2434-3273	3236	2791-3737	2931	2415-3406	2692	2434-3078	0.450
Siglec7 <sup>+</sup> (%)	92.01	90.60-94.46	92.80	89.47-95.50	90.74	87.22-92.72	93.65	90.39-96.00	0.205
Siglec7 <sup>+</sup> (MFI)	5073	4134-6173	5683	4023-6452	5018	3910-5997	5782	3767-6822	0.842
KLRG-1 <sup>+</sup> (%)	2.470	0.745-6.345	9.710	6.703-40.37	20.64	17.87-28.00	4.240	1.560-8.998	<b>&lt;0.0001</b>
KLRG-1 <sup>+</sup> (MFI)	95.20	71.96-143.6	155.3	104.7-415.3	161.9	124.4-222.1	121.6	101.7-162.1	<b>0.021</b>

The distribution of circulating NK cell subsets and their immunophenotype was compared among the patients of HPV16(-) CIN 0 (N = 20), HPV16(+) CIN 0 (N = 11), HPV16(+) CIN I (N = 10) and HPV16(+) CIN II-III (N = 16).

Kruskal–Wallis test was used to determine statistical significance. P values  $\leq 0.05$  were considered statistically significant and are indicated in bold.

## Figures

### Figure 1

Increased number of circulating peripheral blood CD56<sup>bright</sup> NK cells counts in HPV16(+)-related CIN II-III. A (a, b) Representative flow cytometry dot plots from staining to gating of NK cells using CD3<sup>-</sup> CD56<sup>+</sup> as a marker. A (c) A representative dot plot in which two NK cell subsets were gated based on CD56 and CD16 expression: CD56<sup>dim</sup>CD16<sup>bright</sup> and CD56<sup>bright</sup>CD16<sup>negative</sup> NK cells. B (d, e, f) Comparison of the percentage of NK cells and its subsets between the HPV16 CIN 0 and the HPV16(+) CIN groups using violin plots, in which each dot represents a donor. B (g, h, i) Comparison of the absolute count of NK cells and their subsets between the HPV16 CIN 0 and the HPV16(+) CIN groups using violin plots, in which each dot represents a donor. The Kruskal–Wallis test was used to determine statistical significance.

### Figure 2

Circulating CD56<sup>bright</sup> NK cells from HPV16(+) subjects with CIN showed a reduced ability to secrete IFN- $\gamma$ . (A) Representative dot plots of IFN- $\gamma$  and TNF- $\alpha$  expression in the HPV CIN 0 group and HPV16(+) CIN II-III groups; B (a, b) Percentage of CD56<sup>dim</sup> and CD56<sup>bright</sup> NK cells secreting IFN- $\gamma$  and TNF- $\alpha$  in the HPV CIN 0 group; B (c) Statistical graph depicting the percentage of IFN- $\gamma$ -producing CD56<sup>bright</sup> NK cells in HPV16(+) CIN groups; B (d) Statistical graph depicting the percentage of TNF- $\alpha$ -producing CD56<sup>dim</sup> NK cells in HPV16(+) CIN groups; The Kruskal–Wallis test was used to determine statistical significance. The error bars represent the standard deviation.

### Figure 3

Increased expression of TIGIT and KLRG1 expression on CD56<sup>bright</sup> NK cells in HPV16(+)-related CIN. (a - l). The percentage and MFI of positive cells for the inhibitory receptors TIGIT, NKG2A, CD300a, KLRG1, LAIR1, and Siglec-7 were compared between the HPV CIN 0 group and the HPV16(+) CIN groups. The Kruskal–Wallis test was used to test for statistical significance.

### Figure 4

Increased expression of PVR, N-Cadherin and E-Cadherin in HPV16(+)-related CIN. A (a, b, c) Representative legends of PVR, E-Cadherin and N-Cadherin expression in cervical tissues with HPV CIN 0 and HPV16(+) CIN. B (a, b) Summary of the Allred scores in each group. Error bars indicate SD, original magnification: ×200